The independent company being created by a joint venture between Israel's Teva Pharmaceutical Industries and Japan's Takeda Pharmaceutical became a bit more clear this week when the two pharma giants released additional details on their plans.
FiercePharmaAsia 's Matt Driskill discusses the recent conference call held by Benitec Biopharma in Australia in which interim CEO Greg West explains the rather abrupt departure of CEO Peter French and outlines the company's search for a replacement who can bring deep experience in the American market.
Celgene and India's Natco Pharma have announced they settled pending patent litigation, and the terms of the deal mean that Natco will be able to start sales of its generic version of Calgene's multiple myeloma drug Revlimid in the United States more than a year before the drug's patent expires.
India's Aurobindo Pharma is said to be in "advanced talks" with a European company for a $200 million deal that will allow it to acquire permits to market biosimilar drugs for cancers and autoimmune diseases on the continent, according to a report by Livemint.
SciClone Pharmaceuticals said it plans to develop and register its oral mucositis treatment SGX942 for Greater China. The drug is being developed by Soligenix after the two companies entered into a development pact in 2013.
Eli Lilly has joined Halozyme's stable of Big Pharma collaborators, recruiting the company for its drug delivery expertise in a deal worth up to $825 million.
Bayer is making a $335 million wager on the future of gene editing. The pharma company has committed $300 million in research support to a new joint venture with CRISPR Therapeutics that will operate out of Cambridge, MA. And the biotech upstart is grabbing a $35 million equity investment from Bayer, which also signaled a big appetite for more life science deals.
Building on a relationship struck last fall, Bavarian Nordic and Johnson & Johnson's Janssen unit inked a deal on Friday potentially worth $171 million plus milestones aimed at the development of a therapeutic HPV vaccine.
AstraZeneca's research arm MedImmune said it will spend $50 million to expand production in China, and will also expand its manufacturing partnership with WuXi AppTec.
Swedish contract drugmaker Recipharm is on board to help local biotech LIDDS advance its cancer therapy, agreeing to produce the drug and taking an equity stake in its partner.